{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:53:45Z","timestamp":1774565625924,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In the DELIVER trial, eptinezumab administration was associated with sustained reductions in headache frequency and migraine\u2010related impact in participants for whom previous preventive treatments have failed. This\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis evaluated long\u2010term maintenance of initial \u2265\u200950% and \u2265\u200975% migraine response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DELIVER was a 24\u2010week, randomized, double\u2010blind, placebo\u2010controlled trial with a 48\u2010week dose\u2010blinded extension. For participants with initial \u2265\u200950% or \u2265\u200975% reduction in monthly migraine days\u2014defined as response following their first dose (Weeks 1\u201312) or first and second dose (Weeks 1\u201324)\u2014maintenance of \u2265\u200950% or \u2265\u200975% migraine response was assessed for each subsequent 12\u2010week dosing interval. Proportions of severe migraine attacks, 6\u2010Item Headache Impact Test (HIT\u20106) total score, migraine\u2010specific Work Productivity and Activity Impairment (WPAI:M) presenteeism subscore, and Patient Global Impression of Change (PGIC) categories were also evaluated in Weeks 1\u201312 responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of participants with \u2265\u200950% migraine response over Weeks 1\u201312, 61.0% (69\/113, 100\u2009mg) and 73.8% (93\/126, 300\u2009mg) maintained response over the entire 72\u2010week treatment period; \u2265\u200950% responders (Weeks 1\u201324) and \u2265\u200975% responders (Weeks 1\u201312 and 1\u201324) showed similar trends. Weeks 1\u201312 responders (\u2265\u200950% and \u2265\u200975%) experienced sustained reductions in migraine severity, HIT\u20106 total score, and presenteeism subscore, with most reporting improvements per the PGIC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For both eptinezumab doses, \u2265\u200950% or \u2265\u200975% migraine response over Weeks 1\u201312 or 1\u201324 was maintained for the entire 72\u2010week treatment period for many participants. An initial response within the first two doses of eptinezumab can indicate long\u2010term improvements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      (Identifier: NCT04418765; URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04418765\">https:\/\/clinicaltrials.gov\/study\/NCT04418765<\/jats:ext-link>\n                      ); EudraCT (Identifier: 2019\u2013004497\u201025; URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2019-004497-25\">https:\/\/www.clinicaltrialsregister.eu\/ctr\u2010search\/search?query=2019\u2010004497\u201025<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70571","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:45:34Z","timestamp":1773639934000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010Term Improvements Following Initial Migraine Response in Eptinezumab\u2010Treated Participants With Migraine for Whom 2\u20134 Prior Preventive Treatments Have Failed"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4927","authenticated-orcid":false,"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[{"name":"Department of Neurology Georgetown University Hospital  Washington DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-5804","authenticated-orcid":false,"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center Copenhagen University Hospital, Rigshospitalet  Copenhagen Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-7404","authenticated-orcid":false,"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1102-3756","authenticated-orcid":false,"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-8881","authenticated-orcid":false,"given":"Line Pickering","family":"Boserup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-6010","authenticated-orcid":false,"given":"Seema","family":"Soni\u2010Brahmbhatt","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Neurology and the Montefiore Headache Center Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)32160\u20107"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010022\u201001431\u2010x"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105900"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010023\u201001688\u2010w"},{"key":"e_1_2_13_7_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cTechnology Appraisal Guidance: Eptinezumab for Preventing Migraine [TA871] \u201d2023 https:\/\/www.nice.org.uk\/guidance\/TA871."},{"key":"e_1_2_13_8_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cTechnology Appraisal Guidance: Erenumab for Preventing Migraine [TA682] \u201d2021 https:\/\/www.nice.org.uk\/guidance\/TA682."},{"key":"e_1_2_13_9_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cTechnology Appraisal Guidance: Fremanezumab for Preventing Migraine [TA764] \u201d2022 https:\/\/www.nice.org.uk\/guidance\/TA764."},{"key":"e_1_2_13_10_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cTechnology Appraisal Guidance: Galcanezumab for Preventing Migraine [TA659] \u201d2020 https:\/\/www.nice.org.uk\/guidance\/TA659."},{"key":"e_1_2_13_11_1","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) \u201cErenumab (Aimovig): CADTH Common Drug Review \u201d2020 https:\/\/www.cda\u2010amc.ca\/erenumab."},{"key":"e_1_2_13_12_1","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) \u201cFremanezumab (Ajovy): CADTH Reimbursement Recommendation \u201d2021 https:\/\/www.cda\u2010amc.ca\/fremanezumab."},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2023.537"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2022.275"},{"key":"e_1_2_13_15_1","unstructured":"French National Authority for Health \u201cOpinions on Drugs: Eptinezumab (Vyepti) \u201d2022 https:\/\/www.has\u2010sante.fr\/jcms\/p_3382726\/en\/vyepti\u2010eptinezumab."},{"key":"e_1_2_13_16_1","unstructured":"French National Authority for Health \u201cOpinions on Drugs: Fremanezumab (Ajovy) \u201d2022 https:\/\/www.has\u2010sante.fr\/jcms\/p_3367543\/en\/ajovy\u2010fremanezumab."},{"key":"e_1_2_13_17_1","unstructured":"French National Authority for Health \u201cOpinions on Drugs: Galcanezumab (Emgality) \u201d2020 https:\/\/www.has\u2010sante.fr\/jcms\/p_3191463\/en\/emgality."},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010024\u201001793\u20104"},{"key":"e_1_2_13_19_1","unstructured":"\u201cThe Danish Medicines Council's Drug Recommendation in the Case of Medicinal Products for Chronic Migraine \u2013 Inclusion Criteria for Initiation Follow\u2010Up and Discontinuation Version 1.3. Medicinradet \u201d2022 pp. 1\u201310."},{"key":"e_1_2_13_20_1","unstructured":"Institute for Clinical and Economic Review (ICER) \u201cCalcitonin Gene\u2010Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients With Episodic or Chronic Migraine: Effectiveness and Value \u201d2021 https:\/\/icer.org\/wp\u2010content\/uploads\/2020\/10\/ICER_Migraine_Final_Evidence_Report_070318\u20101.pdf."},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251320608"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221095902"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010022\u201001472\u20102"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(22)00185\u20105"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231170807"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026119331193"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053\u2010199304050\u201000006"},{"key":"e_1_2_13_33_1","unstructured":"\u201cWPAI:Migraine. Reilly Associates \u201d2024 http:\/\/www.reillyassociates.net\/WPAI_Translations\u20106.html."},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmpt.2003.11.003"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241291578"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16131"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14302"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010021\u201000509\u20105"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122\u2010019\u20100133\u20101"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70571","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70571","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:13:43Z","timestamp":1774563223000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/ene.70571"],"URL":"https:\/\/doi.org\/10.1111\/ene.70571","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70571"}}